Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin + DHAP in R/R Hodgkin Lymphoma
NCT05243693Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Classical Hodgkin Lymphoma (cHL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Complete Response Rate at 3 months. Started Mar 2022; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT05243693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243693.